首页> 外文OA文献 >Allogeneic MSCs and Recycled Autologous Chondrons Mixed in a One-Stage Cartilage Cell Transplantion: A First-in-Man Trial in 35 Patients
【2h】

Allogeneic MSCs and Recycled Autologous Chondrons Mixed in a One-Stage Cartilage Cell Transplantion: A First-in-Man Trial in 35 Patients

机译:同种异体间充质干细胞和回收的自体软骨细胞混合在单阶段软骨细胞移植中:35位患者的首次试验

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

MSCs are known as multipotent mesenchymal stem cells that have been found capable of differentiating into various lineages including cartilage. However, recent studies suggest MSCs are pericytes that stimulate tissue repair through trophic signaling. Aimed at articular cartilage repair in a one-stage cell transplantation, this study provides first clinical evidence that MSCs stimulate autologous cartilage repair in the knee without engrafting in the host tissue. A phase I (first-in-man) clinical trial studied the one-stage application of allogeneic MSCs mixed with 10% or 20% recycled defect derived autologous chondrons for the treatment of cartilage defects in 35 patients. No treatment-related serious adverse events were found and statistically significant improvement in clinical outcome shown. Magnetic resonance imaging and second-look arthroscopies showed consistent newly formed cartilage tissue. A biopsy taken from the center of the repair tissue was found to have hyaline-like features with a high concentration of proteoglycans and type II collagen. DNA short tandem repeat analysis delivered unique proof that the regenerated tissue contained patient-DNA only. These findings support the hypothesis that allogeneic MSCs stimulate a regenerative host response. This first-in-man trial supports a paradigm shift in which MSCs are applied as augmentations or “signaling cells” rather than differentiating stem cells and opens doors for other applications. Stem Cells 2017;35:1984–1993.
机译:MSC被称为多能间充质干细胞,已被发现能够分化为包括软骨在内的各种谱系。但是,最近的研究表明,MSC是通过营养信号刺激组织修复的周细胞。该研究针对单阶段细胞移植中的关节软骨修复,提供了第一个临床证据,即MSCs刺激了膝盖的自体软骨修复,而没有植入宿主组织。一期(首次人类)临床试验研究了同种异体间充质干细胞与10%或20%再生缺损自体软骨细胞混合应用的一阶段应用,用于治疗35例软骨缺损。未发现与治疗有关的严重不良事件,临床结果显示统计学上的显着改善。磁共振成像和二次关节镜检查显示一致的新形成的软骨组织。从修复组织的中心进行的活检发现具有透明样的特征,并带有高浓度的蛋白聚糖和II型胶原。 DNA短串联重复分析提供了独特的证据,证明再生组织仅包含患者DNA。这些发现支持了同种异体MSC刺激宿主再生反应的假说。该首次试验支持范式转变,在这种转变中,MSC被用作增强或“信号细胞”,而不是分化干细胞,并为其他应用打开了大门。干细胞2017; 35:1984–1993。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号